Default company panoramic image


COOL~BIO is translating cool science into important medicines.

  • Stage Product In Development
  • Industry Biotechnology
  • Location United States
  • Currency USD
  • Founded September 2011
  • Employees 2
  • Website

Company Summary

We are a development-stage biopharmaceutical company that turns exciting science into therapies for patients with serious unmet needs. We focus on products with >$200M in peak revenue that have a defined regulatory path, exploit drug-able targets or well-characterized biological pathways and where proof of concept can be achieved with less than 50 patients. Our lead molecule is a cold-activated antibody to reduce bleeding after cardiac surgery.


  • Default avatar
    Dawn Bell
    President and CEO

    Dawn has over 15 years experience in the strategic development of anti-thrombotic agents including out-licensing/M&A responsibilities. She has worked on successful brands including Integrilin, Angiomax and Cangrelor. Recently she led US operations at Canyon Pharmaceuticals launching Iprivask, winner of the 2011 Frost and Sullivan Product Differentiation Award for Parenteral Anticoagulants. She earned her PharmD from the University of Florida.

  • Default avatar
    Michael Kurz
    Chief Scientific Officer

    Mike has 20 years experience in pre-clinical and clinical cardiovascular research. For the past 10 years he has focused on anti-thrombotic therapies including work on ReoPro, Retevase, the Cypher Stent and Iprivask. Mike earned his PhD in Physiology and Biophysics from the University of Louisville and completed two NIH-funded fellowships in cardiovascular physiology before joining Gensia to head up pre-clinical cardiovascular pharmacology.


  • Default avatar
    Joe La Barge

Previous Investors

  • Default avatar
    Default avatar